_id
690f37f4ccc777a4e85d1825
Ticker
BPTSY
Name
Biophytis S.A.
Exchange
PINK
Address
14 avenue de l'Opéra, Paris, France, 75001
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.biophytis.com
Description
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Last Close
0.011
Volume
-
Current Price
0.011
Change
0
Last Updated
2026-01-20T16:54:59.320Z
Image
-
Ipo Date
-
Market Cap
3002893
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4
Target Price
15
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
-
Cost Of Revenue
226082
Gross Profit
-226082
Operating Expenses
4540210
Operating Income
-4766292
Interest Expense
806032
Pretax Income
-4118627
Net Income
-3782234
Eps
-1.9625661845133946
Dividends Per Share
-
Shares Outstanding
4209163
Income Tax Expense
-335300
EBITDA
-3087609
Operating Margin
-
Total Other Income Expense Net
647665
Cash
1418010
Short Term Investments
-
Receivables
2668161
Inventories
-
Total Current Assets
4506410
Property Plant Equipment
213640
Total Assets
7774408
Payables
-
Short Term Debt
5434925
Long Term Debt
-
Total Liabilities
16952741
Equity
-9137248
Bs_currency_symbol
EUR
Depreciation
226082
Change In Working Capital
185671
Cash From Operations
-4032344
Capital Expenditures
4032344
Cash From Investing
-
Cash From Financing
5266512
Net Change In Cash
1337241
Cf_currency_symbol
-
PE
-
PB
-0.0023200714263200473
ROE
41.39357933592259
ROA
-48.64980073080806
FCF
-8064688
Fcf Percent
-
Piotroski FScore
0
Health Score
38
Deep Value Investing Score
2
Defensive Investing Score
5
Dividend Investing Score
1.5
Economic Moat Investing Score
5.3
Garp Investing Score
2
Growth Investing Score
2
Momentum Investing Score
2.5
Net Net Investing Score
1
Quality Investing Score
3
Value Investing Score
3
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
-
Quarters > 0 > income Statement > cost Of Revenue
226082
Quarters > 0 > income Statement > gross Profit
-226082
Quarters > 0 > income Statement > operating Expenses
4540210
Quarters > 0 > income Statement > operating Income
-4766292
Quarters > 0 > income Statement > interest Expense
806032
Quarters > 0 > income Statement > pretax Income
-4118627
Quarters > 0 > income Statement > net Income
-3782234
Quarters > 0 > income Statement > eps
-1.9625661845133946
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
1927188
Quarters > 0 > income Statement > income Tax Expense
-335300
Quarters > 0 > income Statement > EBITDA
-3087609
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
647665
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
1418010
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
2668161
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
4506410
Quarters > 0 > balance Sheet > property Plant Equipment
213640
Quarters > 0 > balance Sheet > total Assets
7774408
Quarters > 0 > balance Sheet > payables
-
Quarters > 0 > balance Sheet > short Term Debt
5434925
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
16952741
Quarters > 0 > balance Sheet > equity
-9137248
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
-3782234
Quarters > 0 > cash Flow > depreciation
226082
Quarters > 0 > cash Flow > change In Working Capital
185671
Quarters > 0 > cash Flow > cash From Operations
-4032344
Quarters > 0 > cash Flow > capital Expenditures
4032344
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
5266512
Quarters > 0 > cash Flow > net Change In Cash
1337241
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-1.9625661845133946
Quarters > 0 > ratios > PB
-0.0023200714263200473
Quarters > 0 > ratios > ROE
41.39357933592259
Quarters > 0 > ratios > ROA
-48.64980073080806
Quarters > 0 > ratios > FCF
-8064688
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
38
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
4110000
Quarters > 1 > income Statement > operating Income
-4110000
Quarters > 1 > income Statement > interest Expense
745000
Quarters > 1 > income Statement > pretax Income
-4568000
Quarters > 1 > income Statement > net Income
-4567000
Quarters > 1 > income Statement > eps
-6.63407009715056
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
688416
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-3989000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-458000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
78000
Quarters > 1 > balance Sheet > short Term Investments
190000
Quarters > 1 > balance Sheet > receivables
82000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
3925000
Quarters > 1 > balance Sheet > property Plant Equipment
231000
Quarters > 1 > balance Sheet > total Assets
6902000
Quarters > 1 > balance Sheet > payables
4280000
Quarters > 1 > balance Sheet > short Term Debt
9085000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
16604000
Quarters > 1 > balance Sheet > equity
-9668000
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
-4567
Quarters > 1 > cash Flow > depreciation
910
Quarters > 1 > cash Flow > change In Working Capital
-1394
Quarters > 1 > cash Flow > cash From Operations
-2690
Quarters > 1 > cash Flow > capital Expenditures
9
Quarters > 1 > cash Flow > cash From Investing
19
Quarters > 1 > cash Flow > cash From Financing
561
Quarters > 1 > cash Flow > net Change In Cash
-2189
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-6.63407009715056
Quarters > 1 > ratios > PB
-0.0007832618949110467
Quarters > 1 > ratios > ROE
47.23831195697145
Quarters > 1 > ratios > ROA
-66.16922631121413
Quarters > 1 > ratios > FCF
-2699
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
39
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
-
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
4390000
Quarters > 2 > income Statement > operating Income
-4390000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-5817000
Quarters > 2 > income Statement > net Income
-5812000
Quarters > 2 > income Statement > eps
-16.605856621628185
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
349997
Quarters > 2 > income Statement > income Tax Expense
-2.68
Quarters > 2 > income Statement > EBITDA
-4268000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-1427000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
2189000
Quarters > 2 > balance Sheet > short Term Investments
113000
Quarters > 2 > balance Sheet > receivables
3282000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
5744000
Quarters > 2 > balance Sheet > property Plant Equipment
275000
Quarters > 2 > balance Sheet > total Assets
8714000
Quarters > 2 > balance Sheet > payables
3758000
Quarters > 2 > balance Sheet > short Term Debt
8892000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
15132000
Quarters > 2 > balance Sheet > equity
-6385000
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
-5812
Quarters > 2 > cash Flow > depreciation
148
Quarters > 2 > cash Flow > change In Working Capital
31
Quarters > 2 > cash Flow > cash From Operations
-5953
Quarters > 2 > cash Flow > capital Expenditures
9
Quarters > 2 > cash Flow > cash From Investing
-9
Quarters > 2 > cash Flow > cash From Financing
2582
Quarters > 2 > cash Flow > net Change In Cash
-1690
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-16.605856621628185
Quarters > 2 > ratios > PB
-0.000602970555990603
Quarters > 2 > ratios > ROE
91.02584181675802
Quarters > 2 > ratios > ROA
-66.69726876291026
Quarters > 2 > ratios > FCF
-5962
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
39
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
1306000
Quarters > 3 > income Statement > gross Profit
-1306000
Quarters > 3 > income Statement > operating Expenses
7293000
Quarters > 3 > income Statement > operating Income
-7809000
Quarters > 3 > income Statement > interest Expense
982000
Quarters > 3 > income Statement > pretax Income
-9262000
Quarters > 3 > income Statement > net Income
-9262000
Quarters > 3 > income Statement > eps
-48.83758944154728
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
189649
Quarters > 3 > income Statement > income Tax Expense
-2500
Quarters > 3 > income Statement > EBITDA
-7397000
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-1453000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
5567000
Quarters > 3 > balance Sheet > short Term Investments
368000
Quarters > 3 > balance Sheet > receivables
2738000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
8850000
Quarters > 3 > balance Sheet > property Plant Equipment
315000
Quarters > 3 > balance Sheet > total Assets
11960000
Quarters > 3 > balance Sheet > payables
5392000
Quarters > 3 > balance Sheet > short Term Debt
5023000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
15849000
Quarters > 3 > balance Sheet > equity
-3857000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-9262
Quarters > 3 > cash Flow > depreciation
728
Quarters > 3 > cash Flow > change In Working Capital
-297
Quarters > 3 > cash Flow > cash From Operations
-4711
Quarters > 3 > cash Flow > capital Expenditures
130
Quarters > 3 > cash Flow > cash From Investing
1147
Quarters > 3 > cash Flow > cash From Financing
3339
Quarters > 3 > cash Flow > net Change In Cash
-5782
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-48.83758944154728
Quarters > 3 > ratios > PB
-0.0005408708841068187
Quarters > 3 > ratios > ROE
240.13481980814103
Quarters > 3 > ratios > ROA
-77.44147157190635
Quarters > 3 > ratios > FCF
-4841
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
39
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
-
Annuals > 0 > income Statement > cost Of Revenue
0
Annuals > 0 > income Statement > gross Profit
0
Annuals > 0 > income Statement > operating Expenses
8500000
Annuals > 0 > income Statement > operating Income
-8500000
Annuals > 0 > income Statement > interest Expense
1530000
Annuals > 0 > income Statement > pretax Income
-10385000
Annuals > 0 > income Statement > net Income
-10379000
Annuals > 0 > income Statement > eps
-1.9990107987799852
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
5192068
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-8257000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-1885000
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
78000
Annuals > 0 > balance Sheet > short Term Investments
190000
Annuals > 0 > balance Sheet > receivables
82000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
3925000
Annuals > 0 > balance Sheet > property Plant Equipment
231000
Annuals > 0 > balance Sheet > total Assets
6902000
Annuals > 0 > balance Sheet > payables
4280000
Annuals > 0 > balance Sheet > short Term Debt
9085000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
16604000
Annuals > 0 > balance Sheet > equity
-9668000
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
-10379000
Annuals > 0 > cash Flow > depreciation
1058000
Annuals > 0 > cash Flow > change In Working Capital
-1363000
Annuals > 0 > cash Flow > cash From Operations
-8643000
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
10000
Annuals > 0 > cash Flow > cash From Financing
3143000
Annuals > 0 > cash Flow > net Change In Cash
-5492000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
-1.9990107987799852
Annuals > 0 > ratios > PB
-0.0059074004964832436
Annuals > 0 > ratios > ROE
107.35415804716591
Annuals > 0 > ratios > ROA
-150.37670240509996
Annuals > 0 > ratios > FCF
-8643000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
39
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
803000
Annuals > 1 > income Statement > gross Profit
-803000
Annuals > 1 > income Statement > operating Expenses
14333000
Annuals > 1 > income Statement > operating Income
-14333000
Annuals > 1 > income Statement > interest Expense
1251000
Annuals > 1 > income Statement > pretax Income
-18587000
Annuals > 1 > income Statement > net Income
-17026000
Annuals > 1 > income Statement > eps
-125.40510282246184
Annuals > 1 > income Statement > dividends Per Share
0
Annuals > 1 > income Statement > shares Outstanding
135768
Annuals > 1 > income Statement > income Tax Expense
-1561000
Annuals > 1 > income Statement > EBITDA
-13804000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-4254000
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
5567000
Annuals > 1 > balance Sheet > short Term Investments
368000
Annuals > 1 > balance Sheet > receivables
2738000
Annuals > 1 > balance Sheet > inventories
45000
Annuals > 1 > balance Sheet > total Current Assets
8850000
Annuals > 1 > balance Sheet > property Plant Equipment
315000
Annuals > 1 > balance Sheet > total Assets
11960000
Annuals > 1 > balance Sheet > payables
5392000
Annuals > 1 > balance Sheet > short Term Debt
5023000
Annuals > 1 > balance Sheet > long Term Debt
2425000
Annuals > 1 > balance Sheet > total Liabilities
15849000
Annuals > 1 > balance Sheet > equity
-3857000
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
-17026000
Annuals > 1 > cash Flow > depreciation
803000
Annuals > 1 > cash Flow > change In Working Capital
-26000
Annuals > 1 > cash Flow > cash From Operations
-12873000
Annuals > 1 > cash Flow > capital Expenditures
220000
Annuals > 1 > cash Flow > cash From Investing
370000
Annuals > 1 > cash Flow > cash From Financing
7027000
Annuals > 1 > cash Flow > net Change In Cash
-5485000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-125.40510282246184
Annuals > 1 > ratios > PB
-0.00038720456313196786
Annuals > 1 > ratios > ROE
441.43116411718955
Annuals > 1 > ratios > ROA
-142.3578595317726
Annuals > 1 > ratios > FCF
-13093000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
484000
Annuals > 2 > income Statement > gross Profit
-484000
Annuals > 2 > income Statement > operating Expenses
23271000
Annuals > 2 > income Statement > operating Income
-23272000
Annuals > 2 > income Statement > interest Expense
1597000
Annuals > 2 > income Statement > pretax Income
-24216000
Annuals > 2 > income Statement > net Income
-24216000
Annuals > 2 > income Statement > eps
-554.0277746001967
Annuals > 2 > income Statement > dividends Per Share
0
Annuals > 2 > income Statement > shares Outstanding
43709
Annuals > 2 > income Statement > income Tax Expense
-1521000
Annuals > 2 > income Statement > EBITDA
-22787000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-944000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
11053000
Annuals > 2 > balance Sheet > short Term Investments
590000
Annuals > 2 > balance Sheet > receivables
500000
Annuals > 2 > balance Sheet > inventories
1574000
Annuals > 2 > balance Sheet > total Current Assets
18576000
Annuals > 2 > balance Sheet > property Plant Equipment
584000
Annuals > 2 > balance Sheet > total Assets
21987000
Annuals > 2 > balance Sheet > payables
6940000
Annuals > 2 > balance Sheet > short Term Debt
7759000
Annuals > 2 > balance Sheet > long Term Debt
3513000
Annuals > 2 > balance Sheet > total Liabilities
23898000
Annuals > 2 > balance Sheet > equity
-1879000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
-24216000
Annuals > 2 > cash Flow > depreciation
484000
Annuals > 2 > cash Flow > change In Working Capital
-1335000
Annuals > 2 > cash Flow > cash From Operations
-18988000
Annuals > 2 > cash Flow > capital Expenditures
141000
Annuals > 2 > cash Flow > cash From Investing
-17000
Annuals > 2 > cash Flow > cash From Financing
6134000
Annuals > 2 > cash Flow > net Change In Cash
-12873000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-554.0277746001967
Annuals > 2 > ratios > PB
-0.00025588025545502925
Annuals > 2 > ratios > ROE
1288.7706226716339
Annuals > 2 > ratios > ROA
-110.13780870514395
Annuals > 2 > ratios > FCF
-19129000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
311000
Annuals > 3 > income Statement > gross Profit
-311000
Annuals > 3 > income Statement > operating Expenses
26815000
Annuals > 3 > income Statement > operating Income
-26815000
Annuals > 3 > income Statement > interest Expense
4432000
Annuals > 3 > income Statement > pretax Income
-31247000
Annuals > 3 > income Statement > net Income
-31163000
Annuals > 3 > income Statement > eps
-1053.8721677375718
Annuals > 3 > income Statement > dividends Per Share
0
Annuals > 3 > income Statement > shares Outstanding
29570
Annuals > 3 > income Statement > income Tax Expense
2279000
Annuals > 3 > income Statement > EBITDA
-26504000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-4349000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
23926000
Annuals > 3 > balance Sheet > short Term Investments
1229000
Annuals > 3 > balance Sheet > receivables
5118000
Annuals > 3 > balance Sheet > inventories
-709000
Annuals > 3 > balance Sheet > total Current Assets
31366000
Annuals > 3 > balance Sheet > property Plant Equipment
563000
Annuals > 3 > balance Sheet > total Assets
36262000
Annuals > 3 > balance Sheet > payables
7606000
Annuals > 3 > balance Sheet > short Term Debt
12037000
Annuals > 3 > balance Sheet > long Term Debt
4387000
Annuals > 3 > balance Sheet > total Liabilities
30557000
Annuals > 3 > balance Sheet > equity
5835000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
-31247000
Annuals > 3 > cash Flow > depreciation
311000
Annuals > 3 > cash Flow > change In Working Capital
1320000
Annuals > 3 > cash Flow > cash From Operations
-23795000
Annuals > 3 > cash Flow > capital Expenditures
344000
Annuals > 3 > cash Flow > cash From Investing
12160000
Annuals > 3 > cash Flow > cash From Financing
29715000
Annuals > 3 > cash Flow > net Change In Cash
18079000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-1053.8721677375718
Annuals > 3 > ratios > PB
0.000055744644387317906
Annuals > 3 > ratios > ROE
-534.0702656383891
Annuals > 3 > ratios > ROA
-85.93844796205394
Annuals > 3 > ratios > FCF
-24139000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
15
Valuation > metrics > PE
-1.9625661845133946
Valuation > metrics > PB
-0.0023200714263200473
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
41.39357933592259
Profitability > metrics > ROA
-83.93009069303503
Profitability > final Score
55
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-5.913278877265419
Risk > final Score
6
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.8291577160678391
Liquidity > metrics > Quick Ratio
0.8291577160678391
Liquidity > final Score
51
Liquidity > verdict
Weak
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
55
Prev Profitabilities > 1
55
Prev Profitabilities > 2
55
Prev Risks > 0
8
Prev Risks > 1
19
Prev Risks > 2
-2
Prev Liquidities > 0
25
Prev Liquidities > 1
33
Prev Liquidities > 2
52
Updated At
2026-01-20T21:31:19.250Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-10-31
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.18
Earnings History > 0 > eps Estimate
0
Earnings History > 0 > eps Difference
-0.18
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-09-29
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.66
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2024-06-30
Earnings History > 2 > report Date
2024-09-30
Earnings History > 2 > date
2024-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-1.66
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-1.66
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2023-03-31
Earnings History > 3 > report Date
2023-05-25
Earnings History > 3 > date
2023-03-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
0
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2022-12-31
Earnings History > 4 > report Date
2023-03-31
Earnings History > 4 > date
2022-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
0
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2022-09-30
Earnings History > 5 > report Date
2022-10-24
Earnings History > 5 > date
2022-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
0
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2022-03-31
Earnings History > 6 > report Date
2022-05-26
Earnings History > 6 > date
2022-03-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
0
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2021-12-31
Earnings History > 7 > report Date
2022-02-26
Earnings History > 7 > date
2021-12-31
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
-
Earnings History > 7 > eps Actual
0
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2021-09-30
Earnings History > 8 > report Date
2021-12-01
Earnings History > 8 > date
2021-09-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
-
Earnings History > 8 > eps Actual
0
Earnings History > 8 > eps Estimate
0
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2021-06-30
Earnings History > 9 > report Date
2021-09-17
Earnings History > 9 > date
2021-06-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
-
Earnings History > 9 > eps Actual
0
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-06-30)
Rating:
BUY
Target Price:
$15
Analyst Picks
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 0.00% of the total shares of Biophytis S.A.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.18
EPS Estimate
0
EPS Difference
-0.18
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.